PCSK9 and cardiovascular disorder: This raises the question, whether the atherosclerotic process accelerates in RA patients as a result of longer exposure to chronic systemic inflammation, or if RA treatments impact PCSK9 levels and, consequently, lead to an increased risk of cardiovascular disease.